Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/TRA2B_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/TRA2B_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/TRA2B_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/TRA2B_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/TRA2B_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TRA2B_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/TRA2B_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TRA2B_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/TRA2B_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TRA2B_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/TRA2B_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/TRA2B_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TRA2B_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004802632 | Oral cavity | NEOLP | positive regulation of mRNA splicing, via spliceosome | 11/2005 | 22/18723 | 4.74e-06 | 1.01e-04 | 11 |
GO:005068531 | Oral cavity | NEOLP | positive regulation of mRNA processing | 13/2005 | 32/18723 | 1.14e-05 | 2.10e-04 | 13 |
GO:003090013 | Oral cavity | NEOLP | forebrain development | 67/2005 | 379/18723 | 2.54e-05 | 3.99e-04 | 67 |
GO:00485686 | Oral cavity | NEOLP | embryonic organ development | 71/2005 | 427/18723 | 1.12e-04 | 1.34e-03 | 71 |
GO:000974325 | Oral cavity | NEOLP | response to carbohydrate | 45/2005 | 253/18723 | 4.43e-04 | 4.00e-03 | 45 |
GO:003428425 | Oral cavity | NEOLP | response to monosaccharide | 41/2005 | 225/18723 | 4.69e-04 | 4.20e-03 | 41 |
GO:000974624 | Oral cavity | NEOLP | response to hexose | 39/2005 | 219/18723 | 1.00e-03 | 7.68e-03 | 39 |
GO:007132223 | Oral cavity | NEOLP | cellular response to carbohydrate stimulus | 31/2005 | 163/18723 | 1.07e-03 | 8.08e-03 | 31 |
GO:007133323 | Oral cavity | NEOLP | cellular response to glucose stimulus | 29/2005 | 151/18723 | 1.30e-03 | 9.44e-03 | 29 |
GO:000167824 | Oral cavity | NEOLP | cellular glucose homeostasis | 32/2005 | 172/18723 | 1.31e-03 | 9.48e-03 | 32 |
GO:007133123 | Oral cavity | NEOLP | cellular response to hexose stimulus | 29/2005 | 153/18723 | 1.60e-03 | 1.12e-02 | 29 |
GO:007132623 | Oral cavity | NEOLP | cellular response to monosaccharide stimulus | 29/2005 | 154/18723 | 1.78e-03 | 1.22e-02 | 29 |
GO:000974923 | Oral cavity | NEOLP | response to glucose | 36/2005 | 212/18723 | 3.52e-03 | 2.07e-02 | 36 |
GO:00215371 | Oral cavity | NEOLP | telencephalon development | 40/2005 | 248/18723 | 5.50e-03 | 2.93e-02 | 40 |
GO:002198721 | Oral cavity | NEOLP | cerebral cortex development | 21/2005 | 114/18723 | 9.16e-03 | 4.37e-02 | 21 |
GO:004259324 | Oral cavity | NEOLP | glucose homeostasis | 40/2005 | 258/18723 | 1.06e-02 | 4.93e-02 | 40 |
GO:190331116 | Prostate | BPH | regulation of mRNA metabolic process | 111/3107 | 288/18723 | 2.28e-19 | 1.17e-16 | 111 |
GO:000838018 | Prostate | BPH | RNA splicing | 147/3107 | 434/18723 | 5.17e-19 | 2.29e-16 | 147 |
GO:004348418 | Prostate | BPH | regulation of RNA splicing | 71/3107 | 148/18723 | 6.14e-19 | 2.53e-16 | 71 |
GO:005068415 | Prostate | BPH | regulation of mRNA processing | 64/3107 | 137/18723 | 1.73e-16 | 3.82e-14 | 64 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TRA2B | SNV | Missense_Mutation | | c.62G>A | p.Gly21Glu | p.G21E | P62995 | protein_coding | deleterious_low_confidence(0.04) | benign(0.134) | TCGA-A2-A0YM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TRA2B | SNV | Missense_Mutation | rs758758553 | c.221N>A | p.Arg74His | p.R74H | P62995 | protein_coding | tolerated_low_confidence(0.27) | benign(0.375) | TCGA-AR-A254-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
TRA2B | SNV | Missense_Mutation | | c.544A>T | p.Met182Leu | p.M182L | P62995 | protein_coding | tolerated(0.16) | benign(0.079) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TRA2B | SNV | Missense_Mutation | | c.186A>C | p.Arg62Ser | p.R62S | P62995 | protein_coding | tolerated_low_confidence(0.2) | benign(0.012) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TRA2B | SNV | Missense_Mutation | novel | c.734N>C | p.Gly245Ala | p.G245A | P62995 | protein_coding | tolerated_low_confidence(0.07) | possibly_damaging(0.794) | TCGA-XX-A89A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TRA2B | deletion | Frame_Shift_Del | novel | c.821delN | p.Tyr274SerfsTer18 | p.Y274Sfs*18 | P62995 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
TRA2B | SNV | Missense_Mutation | novel | c.772N>G | p.Gln258Glu | p.Q258E | P62995 | protein_coding | tolerated_low_confidence(0.22) | benign(0.042) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TRA2B | SNV | Missense_Mutation | | c.275N>A | p.Arg92Lys | p.R92K | P62995 | protein_coding | deleterious(0.04) | possibly_damaging(0.745) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TRA2B | SNV | Missense_Mutation | novel | c.650N>T | p.Arg217Leu | p.R217L | P62995 | protein_coding | deleterious(0.01) | benign(0.003) | TCGA-JX-A5QV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TRA2B | SNV | Missense_Mutation | novel | c.296N>G | p.Ser99Cys | p.S99C | P62995 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-MY-A5BF-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |